TY - JOUR
T1 - Methadone maintenance treatment and HIV type 1 seroconversion among injecting drug users
AU - Williams, A. B.
AU - McNelly, E. A.
AU - Williams, A. E.
AU - D'Aquila, R. T.
N1 - Funding Information:
This work was supported by Grant DAO 330-02 from the National Institute on Drug Abuse. We thank the clients and staff of the APT Foundation Methadone Programs for their
PY - 1992/1/1
Y1 - 1992/1/1
N2 - When HIV-1 seroconversion status among prospectively followed methadone maintenance clients was analyzed by treatment retention, 1/56 (2%) of those who remained continuously in treatment seroconverted while 8/42 (19%) of those whose methadone treatment was interrupted seroconverted. When controlled for length of follow up, the difference in seroconversion rate was not statistically significant. Subjects in continuous treatment had a seroconversion rate of 0.7 per 100 person years (95% Confidence Interval [Cl] = 0.1, 5.3) and those with interrupted treatment a rate of 4.3 per 100 person years (95% Cl =2.2, 8.6). Subjects in continuous treatment reported less needle sharing (p < 0.0002), fewer needle sharing partners (p < 0.002), fewer sexual partners (p < 0.03), and were more likely to be women (p < 0.01). These data indicate the need for larger studies to evaluate both client and drug treatment program characteristics which might concomitantly increase treatment retention and decrease HIV-1 risk. This study examined whether methadone maintenance treatment decreases drug injection enough to significantly limit HIV-1 transmission among injection drug users (IDU).
AB - When HIV-1 seroconversion status among prospectively followed methadone maintenance clients was analyzed by treatment retention, 1/56 (2%) of those who remained continuously in treatment seroconverted while 8/42 (19%) of those whose methadone treatment was interrupted seroconverted. When controlled for length of follow up, the difference in seroconversion rate was not statistically significant. Subjects in continuous treatment had a seroconversion rate of 0.7 per 100 person years (95% Confidence Interval [Cl] = 0.1, 5.3) and those with interrupted treatment a rate of 4.3 per 100 person years (95% Cl =2.2, 8.6). Subjects in continuous treatment reported less needle sharing (p < 0.0002), fewer needle sharing partners (p < 0.002), fewer sexual partners (p < 0.03), and were more likely to be women (p < 0.01). These data indicate the need for larger studies to evaluate both client and drug treatment program characteristics which might concomitantly increase treatment retention and decrease HIV-1 risk. This study examined whether methadone maintenance treatment decreases drug injection enough to significantly limit HIV-1 transmission among injection drug users (IDU).
UR - http://www.scopus.com/inward/record.url?scp=0026505450&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026505450&partnerID=8YFLogxK
U2 - 10.1080/09540129208251618
DO - 10.1080/09540129208251618
M3 - Article
C2 - 1314099
AN - SCOPUS:0026505450
VL - 4
SP - 35
EP - 41
JO - AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV
JF - AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV
SN - 0954-0121
IS - 1
ER -
